Mouse Models of Cancer Therapy

Identification of non-redundant functions necessary for tumor cell propagation but not for normal tissue maintenance.
Pre-clinical validation of Myc inhibitors as a therapy for multiple cancer types.
Pre-clinical validation of inhibitors of inflammatory components in pancreatic cancer.

Modeling Myc inhibition in mouse models of lung cancer, pancreatic cancer and glioma.
Studying the effects of Myc inhibition in both tumor cells and microenvironment.
Validation of current Myc inhibitors in mouse models of cancer.
Designing the best Myc inhibitor.
Inhibition of mast cells in pancreatic cancer.
Evaluation of the therapeutic impact of anti-inflammatory drugs as therapy in pancreatic cancer.

Team

Principal Investigator

Predoctoral Student

Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011 May; 25(9): 907-16
Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, Doni A, Nebuloni M, Swigart LB, Evan GI, Mantovani A, Locati M. Role of c-Myc in alternative activation of human macrophages and tumor-associated macrophage biology. 2011 Nov;
Whitfield JR, Soucek L. Tumor microenvironment: becoming sick of Myc. 2011 Oct;
Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, Soucek L, Nasi S. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS ONE 2011; 6(7): e22284
Fukazawa T, Maeda Y, Matsuoka J, Yamatsuji T, Shigemitsu K, Morita I, Faiola F, Durbin ML, Soucek L, Naomoto Y. Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Res. 2010 Oct; 30(10): 4193-200